Back

PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease

European Heart Journal - Cardiovascular Pharmacotherapy

26 August 2026
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY

Contributors

Rhonda E Monroe
Rhonda E Monroe

Author

BOOST-Better Outcomes Optimal Scientific Therapies Charlotte , United States of America

Nikolaus Marx
Nikolaus Marx

Author

RWTH University Hospital Aachen Aachen , Germany

Darren K McGuire
Darren K McGuire

Author

University of Texas Southwestern Medical Center Dallas , United States of America

You may be interested in
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.
31 August 2024
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025
thumbnail
Congress Presentation
Semaglutide and dapagliflozin synergistically prevent cancer therapy-related cardiac dysfunction in hyperglycemic conditions
4 April 2025

ESC 365 is supported by

Lilly Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources